The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Targeted Alpha Therapy For Metastatic Breast Cancer Using Alpha-Herceptin
Funder
National Health and Medical Research Council
Funding Amount
$332,420.00
Summary
The specific aim of this proposal is to demonstrate, in non-human primates, proof–of-concept of a patented new platform vaccine technology (scrambled antigen vaccine or SAVINE) designed to encode all the protein sequences of an infectious agent, in this case HIV-1. These are arranged as equal-sized, overlapping fragments such that all potential T cell epitopes that are needed to induce broad T-cell-mediated immunity are maintained. The synthetically designed vaccine uses consensus sequences of H ....The specific aim of this proposal is to demonstrate, in non-human primates, proof–of-concept of a patented new platform vaccine technology (scrambled antigen vaccine or SAVINE) designed to encode all the protein sequences of an infectious agent, in this case HIV-1. These are arranged as equal-sized, overlapping fragments such that all potential T cell epitopes that are needed to induce broad T-cell-mediated immunity are maintained. The synthetically designed vaccine uses consensus sequences of HIV-1 to provide universal coverage of the major HIV-1 strains for a global population. The synthetic systematically designed HIV-1 vaccine will be delivered using our newly developed prime-boost immunisation regime that induces particularly high levels of cell-mediated immunity.Read moreRead less
The Development Of Store Operated Calcium Channel Monoclonal Antibody Inhibitors As A Therapeutic Option For Breast Cancer Treatment
Funder
National Health and Medical Research Council
Funding Amount
$230,753.00
Summary
Despite recent advances in the treatment of breast cancer, a significant proportion of women with this disease receive little benefit from currently available treatments and die from breast cancer. Hence, new therapies for the breast cancers with the poorest prognosis are needed. This grant exploits our earlier finding that a specific calcium channel is a likely therapeutic target for breast cancer. Funding from this grant will be used to develop an inhibitory monoclonal antibody to this target.
Novel Vaccine Formulation For Immunotherapy Of Adenocarcinomas
Funder
National Health and Medical Research Council
Funding Amount
$178,400.00
Summary
We have designed a vaccine based on a unique delivery system. Mice immunised with vaccine were protected from a tumour challenge. We will now design a vacine with a cancer associated protein so that people once immunised can make killer cells. Since humans have different genetic makeup we will produce a vacine which is more effective and will benefit everyone. This vaccine will be more effective than a current vacine in that has yielded promising results in humans.
Development And Application Of A Pressure-sensing Electropalatograph For The Assessment And Treatment Of Speech Disorder
Funder
National Health and Medical Research Council
Funding Amount
$200,750.00
Summary
A multidisciplinary team of researchers aim to develop a unique, advanced, computer-based speech device that speech pathologists can use to assess and treat a variety of speech disorders. The device will record the location, timing and pressure of tongue contacts against the roof of the mouth (palate) during speech using innovative sensors embedded in an artificial plate placed over the roof of the mouth. State-of-the-art 3D graphics will be used to display tongue-to-palate contacts to both spee ....A multidisciplinary team of researchers aim to develop a unique, advanced, computer-based speech device that speech pathologists can use to assess and treat a variety of speech disorders. The device will record the location, timing and pressure of tongue contacts against the roof of the mouth (palate) during speech using innovative sensors embedded in an artificial plate placed over the roof of the mouth. State-of-the-art 3D graphics will be used to display tongue-to-palate contacts to both speech pathologist and patient.Read moreRead less
Translation Of MRS For Determining Human Pathology Into The Clinic: Acceptance Testing For Breast, Prostate And Barrett'
Funder
National Health and Medical Research Council
Funding Amount
$160,000.00
Summary
Magnetic resonance spectroscopy (MRS), for many organs, provides the pathological diagnosis with an accuracy approaching 100%. In the case of breast lesions, it discriminates accurately between benign and malignant and, for overt carcinomas, predicts the status of the regional lymph nodes without the need to biopsy the node. For some lesions, such as Barrett’s oesophagus, distinction between dysplasia’s of no immediate concern to the patient and those apparently committed to early progression to ....Magnetic resonance spectroscopy (MRS), for many organs, provides the pathological diagnosis with an accuracy approaching 100%. In the case of breast lesions, it discriminates accurately between benign and malignant and, for overt carcinomas, predicts the status of the regional lymph nodes without the need to biopsy the node. For some lesions, such as Barrett’s oesophagus, distinction between dysplasia’s of no immediate concern to the patient and those apparently committed to early progression to clinical cancer, can be made by the MRS method. A statistical classification method, (SCS) has been developed whereby there are now mathematical classifiers available for the testing acceptance of the method in the clinical setting. Acceptance testing of MRS technology, with the mathematical classifiers integrated in the automated software, for the pathology and prognosis from a biopsy specimen in: · Breast clinic (Dr Malycha, Royal Adelaide) for both pathology and nodal involvement from fine needle aspiration biopsy · Gastrointestinal clinic (Dr Falk. Strathfield Private) for Barrett’s oesophagus · Urology clinic (Dr Katelaris, Sydney Adventist Hospital) for prostate.Read moreRead less
NaviGAIT: New Software To Simplify Interpretation Of Gait Analysis Data
Funder
National Health and Medical Research Council
Funding Amount
$179,905.00
Summary
NaviGAIT is a new software package to support interpretation of gait analysis data. It is based upon Gait Profiling, a new technique to reduce the complexity of such data. At present data intepretation is restricted to a few expert clinicians. The new software will allow non-expert clinicians to interpret data and hence make gait analysis more accessible, cheaper and more clincally useful. A module of NaviGAIT specifically for children with cerebral palsy will be the first to be developed.
Mechanical Mobility Of The Thorax For Continuous Determination Of Lung Gas Volume
Funder
National Health and Medical Research Council
Funding Amount
$165,000.00
Summary
Percussion is a valuable clinical method for physical examination of parts of the body. A sharp tap (impulsive force) is applied to the body wall and the sound radiated in response is observed. This sound may be dull (over liver) or stony dull (pleural effusion), or resonant (over normal lung) or hyper-resonant (over bowel). While the variation in radiated sound is not fully understood, it is apparent that the presence of gas, which is highly compliant, increases mobility of the overlying tissue ....Percussion is a valuable clinical method for physical examination of parts of the body. A sharp tap (impulsive force) is applied to the body wall and the sound radiated in response is observed. This sound may be dull (over liver) or stony dull (pleural effusion), or resonant (over normal lung) or hyper-resonant (over bowel). While the variation in radiated sound is not fully understood, it is apparent that the presence of gas, which is highly compliant, increases mobility of the overlying tissue and allows it to resonate; where the sub-tissue is largely fluid, tissue mobility is low and the percussive sound is dull. Percussion is useful for examining the adult chest and lung, but cannot for example be applied in infant intensive care as only limited impulsive force can be used, and the adult finger, which is both a coupling device and sounding board, is too large. As well, percussion requires skill and quiet conditions. Accordingly, we developed a device to measure mobility of the chest and other tissues in real time. The VibroPulse applies a known low-level force to the body surface and records the resultant velocity induced in the surface. The force is generated by a vibrating mass set in motion by an electromagnetic motor driven by pseudo-random noise. Tissue mobility, defined as velocity-force, is derived simultaneously across the frequency range, providing an easily interpreted quantitative output unaffected by ambient noise. This proposal has two aims we can achieve in 1 year: (1) to continue evaluating VibroPulse sensitivity to tissue composition, using symmetrical percussive sites on the human chest and abdomen that are dull on one side and resonant on the other, and the chest of anaesthetised animals with experimentally induced pneumothorax and lung collapse, two life-threatening conditions for which percussion is a key diagnostic method, and (2) to engineer a small device from our bulky prototype that is suitable for clinical use, in infants and adults.Read moreRead less
Development Of Modified IGF-binding Proteins As Novel Anti-cancer Chemotherapeutics
Funder
National Health and Medical Research Council
Funding Amount
$77,375.00
Summary
We propose to enhance the effectiveness of current anti-cancer treatments by co-administering a protein to sequester growth factors that promote the resistance of cancer cells to chemotherapy. We aim to achieve improved destruction of breast and colorectal cancers but with reduced adverse side effects. Our in vitro data show the effectiveness of this novel co-therapeutic which is a modified form of a natural carrier protein for these growth factors. This application seeks funding to enable proof ....We propose to enhance the effectiveness of current anti-cancer treatments by co-administering a protein to sequester growth factors that promote the resistance of cancer cells to chemotherapy. We aim to achieve improved destruction of breast and colorectal cancers but with reduced adverse side effects. Our in vitro data show the effectiveness of this novel co-therapeutic which is a modified form of a natural carrier protein for these growth factors. This application seeks funding to enable proof of concept in vivo in order to attract commercial funding for clinical trials.Read moreRead less
In Vitro And In Vivo Assessment Of The Funhaler -an Innovative Therapeutic Device For Children
Funder
National Health and Medical Research Council
Funding Amount
$472,750.00
Summary
Aerosol therapy is the most effective form of treatment for children with respiratory diseases such as asthma. While optimising aerosol delivery systems has an important role in increasing the efficacy of asthma therapy, ensuring patient compliance is often the most difficult part of the clinician's role, particularly in the paediatric age group. An innovative small volume spacer device (Funhaler) developed by a West Australian company (InfaMed, Ltd) may help overcome this problem. The Funhaler ....Aerosol therapy is the most effective form of treatment for children with respiratory diseases such as asthma. While optimising aerosol delivery systems has an important role in increasing the efficacy of asthma therapy, ensuring patient compliance is often the most difficult part of the clinician's role, particularly in the paediatric age group. An innovative small volume spacer device (Funhaler) developed by a West Australian company (InfaMed, Ltd) may help overcome this problem. The Funhaler incorporates a spinning toy attached to the outside of the spacer. The toy is activated when the patient breathes through the spacer. The device has been designed to encourage children to co-operate when their asthma therapy is being delivered. The Funhaler is currently in the late development stage. We propose, firstly, to carry out in vitro assessments of drug delivery from the Funhaler compared to the two most widely available small volume spacers: the Aerochamber Plus (Trudell, Canada) and the Breath-A-Tech (Scott-Dibben, Australia). These assessments will be carried out to meet the standards of regulatory bodies worldwide (including the FDA). Secondly, we propose to perform extensive in vivo studie: filter studies to assess drug delivery to the patient; deposition studies to measure drug deposition in the lungs; and a pilot clinical trial to assess the efficacy of the device during medium to long-term use in children aged 2-8 years.Read moreRead less